COP vs TMO: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-04.
ConocoPhillips · Energy
$125.78
+7.3% upside to fair value
Grade C
VS
Thermo Fisher Scientific Inc. · Healthcare
$462.60
+10.1% upside to fair value
Grade B
QuantHub Verdict
TMO has more upside to fair value
(+10.1%).
COP trades at a lower forward P/E
(21.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
TMO |
| Current Price |
$125.78 |
$462.60 |
| Fair Value Estimate |
$134.90 |
$509.20 |
| Upside to Fair Value |
+7.3%
|
+10.1%
|
| Market Cap |
$153.3B |
$171.9B |
| Forward P/E |
21.0x
|
25.1x
|
| EV / EBITDA |
7.5x
|
19.0x
|
| Price / Sales |
2.6x
|
3.8x
|
| Price / FCF |
8.4x
|
25.5x
|
| Revenue Growth YoY |
-2.5%
|
+6.2%
|
| Gross Margin |
33.1%
|
39.4%
|
| Operating Margin |
25.4%
|
17.8%
|
| Return on Equity |
11.3%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
11.96%
|
3.92%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
ConocoPhillips is a leading independent oil and gas exploration and production company with a strong focus on low-cost shale assets and sustainability initiatives. The company benefits from a durable competitive position due to its cost advantage and early ESG leadership, but faces near-term earnings pressure as revenue declined 2.5% and earnings fell 23.4% in the most recent quarter year-over-ye…
Thermo Fisher Scientific Inc. operates in the healthcare sector, specializing in medical diagnostics and research tools across four main segments: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company demonstrates medium business quality with steady revenue growth of 6.2% and earnings growth of 9.6% in the most recent q…
Accumulation Zones
| Metric |
COP |
TMO |
| Zone Low |
$101.18 |
$381.90 |
| Zone High |
$114.67 |
$432.82 |
| In Buy Zone? |
No
|
No
|